L. Delens

Xenogeneic Graft-Versus-Host Disease in Humanized NSG and NSG-HLA-A2/HHD Mice

P. Delvenne, H. Lehrach, F. Baron, 2018, Front. Immunol..

Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model

F. Baron, L. Seidel, G. Ehx, 2019, Front. Immunol..

The use of mesenchymal stromal cells in solid organ transplantation

F. Jouret, J. Krzesinski, L. Delens, 2014 .

Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

F. Baron, L. Seidel, M. Hannon, 2015, PloS one.

Azacytidine Enhances Regulatory T-Cells In Vivo and Prevents Experimental Xenogeneic Graft-Versus-Host Disease

F. Baron, L. Leval, S. Lucas, 2016 .

Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

F. Baron, G. Ehx, M. Hannon, 2016, Expert opinion on investigational drugs.

In Vitro Th17-Polarized Human CD4+ T Cells Exacerbate Xenogeneic Graft-versus-Host Disease.

F. Baron, L. Seidel, G. Ehx, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects

F. Baron, L. de Leval, S. Lucas, 2017, Oncoimmunology.

Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease

P. Delvenne, F. Baron, G. Ehx, 2016, Journal of Hematology & Oncology.

Comprehensive analysis of the immunomodulatory effects of rapamycin on human T cells in graft‐versus‐host disease prophylaxis

F. Baron, G. Ehx, Caroline Ritacco, 2021, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.